Welcome to our dedicated page for Celularity SEC filings (Ticker: CELUW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Unraveling Celularity’s SEC disclosures can feel like decoding a lab notebook. Each 10-K packs dense science on placental-derived cell therapy pipelines, manufacturing scale-ups in New Jersey, and revenue from its Lifebank biobanking arm. If you just want to know whether a delayed trial impacts cash burn or how executives price stock options, digging through EDGAR is slow and error-prone.
Stock Titan’s AI transforms those filings into plain-English answers. Need the latest “Celularity quarterly earnings report 10-Q filing” or wonder, “What does Celularity report in their SEC filings?” Our platform streams documents the instant they post, then highlights critical numbers, red-flags risk factors, and links directly to “Celularity 8-K material events explained.” You can even set alerts for “Celularity insider trading Form 4 transactions” to spot buying or selling before headlines.
- 10-K annual report: Pipeline milestones, segment revenue, GMP facility costs—“Celularity annual report 10-K simplified.”
- 10-Q quarterly update: Clinical spend trends and cash runway, ideal for “Celularity earnings report filing analysis.”
- 8-K current report: Trial holds, licensing deals, CFO departures—all “understanding Celularity SEC documents with AI.”
- Form 4: “Celularity Form 4 insider transactions real-time” plus historical charts of executive stock moves.
- DEF 14A proxy: “Celularity proxy statement executive compensation” distilled into clear tables.
Researchers track manufacturing capacity; portfolio managers monitor “Celularity executive stock transactions Form 4”; biotech analysts compare NK-cell programs across peers. Whatever your angle, our AI-powered summaries, expert context, and real-time feeds keep you ahead—without wading through 200 pages of immunology jargon.
Celularity Inc. reported unaudited interim financials showing a wide operating deficit and continued liquidity pressure. The company had an accumulated deficit of $944,025 and total current assets of $17,263 versus total current liabilities of $69,227, indicating current liabilities materially exceed short-term resources. The filing discloses substantial outstanding debt subject to forbearance agreements, and management states the company expects to continue incurring significant operating losses and using net cash for operations. Warrant liabilities rose to $8,780 from $3,264, and the company recorded losses on debt extinguishment (including $5,736) during the six months ended June 30, 2025. Material financing and restructuring activities noted include PIPE and registered-direct financings (e.g., $6,000 January 2024 PIPE) and planned asset transactions (Asset Purchase Agreement for $33,812) to address indebtedness.
Celularity, Inc. reported interim results in a Form 10-Q for the quarter ended March 31, 2025. The company had $22,080 of current assets and $58,690 of current liabilities, reflecting a working capital deficit. Total long-term related‑party debt was $36,492 and warrant liabilities increased to $8,067 as of March 31, 2025. Accumulated deficit was $919,501. Net revenues from services were $1,408 for the quarter, up 9.4% from $1,287 year‑over‑year, while loss before income taxes narrowed to $(19,754) from $(22,013). The filing discloses multiple debt facilities, forbearance arrangements and convertible note terms, material warrant and contingent consideration balances, and ongoing litigation and settlement items. The company states it expects to continue incurring operating losses and using cash for operations.
Lincoln Alternative Strategies LLC reported beneficial ownership of 1,230,769 shares of Celularity Inc. Class A common stock, representing 5.14% of the class based on 23,949,229 shares outstanding as of August 26, 2025. The filing on a Schedule 13G discloses that the reporting person has sole voting and dispositive power over these shares and certifies the holdings were not acquired to change or influence control of the issuer. The document lists the reporting person’s principal address in Miami Beach, FL, and the issuer’s principal executive office in Florham Park, NJ.
Celularity Inc. entered a Series Seed Preferred Stock Purchase Agreement with Defeye, Inc., receiving 7,198.630 shares of Series Seed-2 Preferred Stock in exchange for $2,890,250 of product purchase credits under their supply and distribution arrangement.
The company also disclosed that Nasdaq notified it of noncompliance for failing to timely file its quarterly report for the period ended March 31, 2025. The company submitted a plan to Nasdaq and was informed it has until August 31, 2025 to file required reports for the periods ended March 31, 2025 and June 30, 2025; failure to meet the exception could lead to delisting, with an appeal available to a Hearings Panel. The filing lists the form of the purchase agreement as Exhibit 10.1 and interactive XBRL cover page as Exhibit 104.
FAQ
What is the current stock price of Celularity (CELUW)?
